BBNX vs PODD
BBNX: Beta Bionics is a medical device company developing automated insulin delivery systems to simplify diabetes management. PODD: Insulet Corporation provides tubeless, wearable insulin management technology that simplifies diabetes care for millions of patients worldwide.
Side-by-side fundamentals
| Metric | BBNX | PODD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $16.31 | $158.93 | |
| Market cap as of 2026-07-23 | $780M | $11.3B | |
| P/E as of 2026-07-23 | n/a | 37.44 | |
| PEG as of 2026-07-23 | n/a | 1.23 | |
| Net margin as of 2026-07-23 | -60.3% | +10.4% | PODD higher |
| Gross margin as of 2026-07-23 | +57.1% | +71.0% | PODD higher |
| Operating margin as of 2026-07-23 | -70.1% | +14.6% | PODD higher |
| ROE as of 2026-07-23 | -23.0% | +17.4% | PODD higher |
| ROA as of 2026-07-23 | -20.5% | +7.5% | PODD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.63 | BBNX lower |
| Revenue growth (YoY) as of 2026-07-23 | +56.6% | +31.9% | BBNX higher |
| Revenue CAGR (3y) SEC XBRL | +189.1% | +27.5% | BBNX higher |
| Beta as of 2026-07-23 | 0.50 | 1.10 | |
| 1-year return as of 2026-07-22 close | +23.2% | -44.3% | BBNX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.